Literature DB >> 727570

Acute theophylline intoxication. Biphasic first order elimination kinetics in a child.

G J Kadlec, C H Jarboe, S J Pollard, J L Sublett.   

Abstract

An acute theophylline intoxication in a child is reported. It was characterized by two distinct first-order elimination processes with t1/2 = 12.6 hr (ke = 0.056 hr-1) and t1/2 = 5.4 hr (ke = 0.128 hr1), respectively. It is proposed that the slower process, which was seen at high plasma levels, represents renal plus saturated hepatic elimination. The later, more rapid process seen at therapeutic plasma levels is consistent with hepatic elimination by biotransformation.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 727570

Source DB:  PubMed          Journal:  Ann Allergy        ISSN: 0003-4738


  11 in total

1.  In vitro--in vivo correlation of dissolution, a time scaling problem? Transformation of in vitro results to the in vivo situation, using theophylline as a practical example.

Authors:  D Brockmeier; H J Dengler; D Voegele
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

2.  Bioavailability and pharmacokinetics of theophylline following plain uncoated and sustained-release dosage forms in relation to smoking habit. II. Multiple dose study.

Authors:  T Ishizaki; Y Horai; T Sasaki; K Chiba; A Ohnishi; T Suganuma; G Tsujimoto; H Echizen; T Okaniwa
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Measurement of excretion characteristics of theophylline and its major metabolites.

Authors:  J H Jonkman; D Tang; R A Upton; S Riegelman
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

4.  Serum level monitoring of a new slow release theophylline formulation in patients with chronic lung disease.

Authors:  G E Marlin; M A Butcher; J A Klumpp; P J Thompson
Journal:  Br J Clin Pharmacol       Date:  1980-09       Impact factor: 4.335

5.  Evaluation of the absorption from 15 commercial theophylline products indicating deficiencies in currently applied bioavailability criteria.

Authors:  R A Upton; L Sansom; T W Guentert; J R Powell; J F Thiercelin; V P Shah; P E Coates; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1980-06

Review 6.  Theophylline poisoning. Pharmacological considerations and clinical management.

Authors:  P Gaudreault; J Guay
Journal:  Med Toxicol       Date:  1986 May-Jun

7.  Urine flow-dependence of theophylline renal clearance in man.

Authors:  D D Tang-Liu; T N Tozer; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1982-08

Review 8.  Pharmacokinetic considerations in clinical toxicology: clinical applications.

Authors:  Darren M Roberts; Nick A Buckley
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

9.  Pharmacokinetics of sustained release theophylline in low and high multidose regimens.

Authors:  G H Koëter; J H Jonkman; K de Vries; R Schoenmaker; J E Greving; R A de Zeeuw
Journal:  Br J Clin Pharmacol       Date:  1981-11       Impact factor: 4.335

10.  Dose-dependency of theophylline clearance and protein binding.

Authors:  J A Fleetham; C E Bird; K Nakatsu; R D Wigle; P W Munt
Journal:  Thorax       Date:  1981-05       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.